Georges Chahoud, MD
Cardiovascular Disease · Saint Louis, MONPI 1942390414
Payments from drug & device makers
Across 1,086 payments — averaging $890.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$218K
- Merck$168K
- Abiomed$166K
- Novartis$89K
- AstraZeneca$81K
- Scpharmaceuticals Inc.$72K
- plus $173K from 28 others
What the payments were for
- Consulting fees$74,6268%
- Speaking & faculty fees$703,56675%
- Travel & lodging$117,20513%
- Food & beverage$41,1094%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 249 | $218,052 |
| Merck | 159 | $168,091 |
| Abiomed | 182 | $166,104 |
| Novartis | 62 | $89,172 |
| AstraZeneca | 104 | $81,328 |
| Scpharmaceuticals Inc. | 59 | $71,748 |
| Boehringer Ingelheim | 51 | $56,559 |
| Bayer | 23 | $30,853 |
| Cvrx, Inc. | 35 | $26,023 |
| Lexicon Pharmaceuticals, Inc. | 32 | $21,329 |
| Abbott | 61 | $15,110 |
| Lilly USA, LLC | 7 | $6,896 |
| Vifor Pharma, Inc. | 2 | $5,201 |
| Edwards Lifesciences | 12 | $3,407 |
| Impulse Dynamics (USA) Inc. | 9 | $2,662 |
| Medtronic(2 entities) | 14 | $1,523 |
| Biotronik Inc. | 1 | $1,200 |
| Qorumpartners | 3 | $373 |
| Novo Nordisk | 3 | $242 |
| Amgen | 4 | $153 |
| Globus Medical | 1 | $132 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $130 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Nevro Corp. | 1 | $123 |
| Itamar Medical Inc | 1 | $123 |
| AbbVie | 1 | $100 |
| Sanofi | 1 | $100 |
| Endotronix, Inc. | 1 | $97 |
| American Regent | 1 | $75 |
| KCI USA, Inc. | 1 | $66 |
| Penumbra, Inc. | 1 | $45 |
| Pfizer | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$261,845
- LifeVest$183,659
- Impella$128,461
- ENTRESTO$86,788
- FUROSCIX$71,065
- FARXIGA$70,857
- JARDIANCE$62,865
- Kerendia$30,543
- Barostim Neo System$25,431
- Inpefa$20,823
- MitraClip$8,023
- Veltassa$5,201
- OPTIMIZER$4,718
- CardioMEMS HF System$2,628
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,628
- CARDIOMEMS$2,152
- LEQVIO$1,688
- COREVALVE EVOLUT R$898
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$680
- SAPIEN 3 Ultra RESILIA$540
How this compares
$967,204 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,502 | $1,461,131 |
| FarxigaDapagliflozin Propanediol | 1,014 | $860,241 |
| EntrestoSacubitril/Valsartan | 769 | $733,178 |
| JardianceEmpagliflozin | 613 | $542,498 |
| XareltoRivaroxaban | 221 | $235,080 |
| BrilintaTicagrelor | 94 | $79,260 |
| Repatha SureclickEvolocumab | 51 | $49,143 |
| CorlanorIvabradine Hcl | 56 | $43,193 |
| VerquvoVericiguat | 47 | $35,832 |
| MultaqDronedarone Hcl | 19 | $23,159 |
| Metoprolol Succinate | 1,727 | $18,125 |
| DapagliflozinDapagliflozin Propanediol | 32 | $16,552 |
| Repatha SyringeEvolocumab | 15 | $14,441 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $13,725 |
| Ranolazine ErRanolazine | 143 | $12,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $1,461,1311,502 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $81,328 | $953,2261,124 claims |
| NovartisEntresto | $89,172 | $733,178769 claims |
| Boehringer IngelheimJardiance | $56,559 | $542,498613 claims |
| AmgenCorlanor | $153 | $43,19356 claims |
| MerckVerquvo | $168,091 | $35,83247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Mohammad TahirSaint Louis$2.7M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Jiafu OuSaint Louis$853K
- William BowenSaint Louis$726K
- Mustafa HusainiSaint Louis$465K
- Denise JanosikSaint Louis$295K
- Farhan KatchiSaint Louis$245K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.